Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Dependence plots further showed that a declining log 25(OH)D slope was associated with an accelerated rise in PTH, particularly in the context of concurrent kidney function decline (Figure 1 and Figure 5).

Source: 3.6. PTH Trajectories. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Animal research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This study used data from the CAN-AIM to PREVENT Trial, a prospective, observational cohort study conducted in Toronto, Ontario, Canada, between 2010 and 2015 (ClinicalTrials.gov Identifier: ).

Source: Methods.

MICE was selected because it iteratively imputes missing variables using robust regression models conditional on all other available data.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Modeling Longitudinal Relationships Between CKD-MBD Biomarker Trajectories with Interpretable Machine Learning in a Large Prospective CKD Cohort

Cohort study · Journal of Clinical Medicine · 2026

Original publication title

Modeling Longitudinal Relationships Between CKD-MBD Biomarker Trajectories with Interpretable Machine Learning in a Large Prospective CKD Cohort

Tolgay Taskapan; Hulya Taskapan; Antonio Bellasi; Sara Mahdavi; Haley Ma; Paul Tam; Tabo Sikaneta

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background/Objectives:

Chronic kidney disease: mineral and bone disorder (CKD-MBD) is characterized by complex interactions between parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), phosphate, calcium, and vitamin D, yet clinical decisions are often based on static individual values. A trajectory-based approach that considers how longitudinal changes in CKD-MBD biomarkers relate to each other may provide a more integrated understanding.

Methods:

In 1968 adults with non-dialysis CKD (mean age 68 ± 12 years; 34% female; mean follow-up duration 3.02 ± 0.35 years), annualized slopes of CKD-MBD biomarkers (PTH, FGF23, phosphate, calcium) were derived from mixed-effects models, alongside slopes and intra-individual variability of other key features of CKD: eGFR, hemoglobin, albumin, bicarbonate, 25-hydroxyvitamin D, uric acid, urine albumin creatinine ratio (UACR). These 36 features, including baseline levels, were evaluated using Extreme Gradient Boosting regression with interpretability via SHapley Additive exPlanations (SHAP).

Results:

Models explained substantial variance in biomarker slopes (R2: 0.86 for PTH, 0.72 for FGF23, 0.71 for phosphate, 0.67 for calcium) without evidence of overfitting. Baseline values and eGFR slopes showed the strongest associations with biomarker trajectories. PTH and FGF23 slopes were positively correlated, while declining hemoglobin and greater hemoglobin variability were associated with steeper FGF23 and phosphate slopes. Phosphate slopes were associated with UACR slopes and bicarbonate slopes. Declining 25(OH)D slopes were linked with rising PTH slopes.

Conclusions:

This analysis revealed consistent relationships between CKD-MBD biomarker trajectories. Longitudinal changes in kidney function, hemoglobin, bicarbonate, UACR, and vitamin D were also associated with biomarker trajectories. Our findings confirm the multi-system nature of CKD-MBD, and provide a framework for examining potentially modifiable pathways in its progression.

An extract from the source publication. Read it in context.

At a glance

Abstract: Background/Objectives

Chronic kidney disease: mineral and bone disorder (CKD-MBD) is characterized by complex interactions between parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), phosphate, calcium, and vitamin D, yet clinical decisions are often based on static individual values. A trajectory-based approach that considers how longitudinal changes in CKD-MBD biomarkers relate to each other may provide a more integrated understanding.

Source: Background/Objectives:

Abstract: Results

Models explained substantial variance in biomarker slopes (R2: 0.86 for PTH, 0.72 for FGF23, 0.71 for phosphate, 0.67 for calcium) without evidence of overfitting. Baseline values and eGFR slopes showed the strongest associations with biomarker trajectories. PTH and FGF23 slopes were positively correlated, while declining hemoglobin and greater hemoglobin variability were associated with steeper FGF23 and phosphate slopes. Phosphate slopes were associated with UACR slopes and bicarbonate slopes. Declining 25(OH)D slopes were linked with rising PTH slopes.

Source: Results

Abstract: Conclusions

This analysis revealed consistent relationships between CKD-MBD biomarker trajectories. Longitudinal changes in kidney function, hemoglobin, bicarbonate, UACR, and vitamin D were also associated with biomarker trajectories. Our findings confirm the multi-system nature of CKD-MBD, and provide a framework for examining potentially modifiable pathways in its progression.

Source: Conclusions
Authors’ abstract

Background/Objectives:

Chronic kidney disease: mineral and bone disorder (CKD-MBD) is characterized by complex interactions between parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), phosphate, calcium, and vitamin D, yet clinical decisions are often based on static individual values. A trajectory-based approach that considers how longitudinal changes in CKD-MBD biomarkers relate to each other may provide a more integrated understanding.

Methods:

In 1968 adults with non-dialysis CKD (mean age 68 ± 12 years; 34% female; mean follow-up duration 3.02 ± 0.35 years), annualized slopes of CKD-MBD biomarkers (PTH, FGF23, phosphate, calcium) were derived from mixed-effects models, alongside slopes and intra-individual variability of other key features of CKD: eGFR, hemoglobin, albumin, bicarbonate, 25-hydroxyvitamin D, uric acid, urine albumin creatinine ratio (UACR). These 36 features, including baseline levels, were evaluated using Extreme Gradient Boosting regression with interpretability via SHapley Additive exPlanations (SHAP).

Results:

Models explained substantial variance in biomarker slopes (R2: 0.86 for PTH, 0.72 for FGF23, 0.71 for phosphate, 0.67 for calcium) without evidence of overfitting. Baseline values and eGFR slopes showed the strongest associations with biomarker trajectories. PTH and FGF23 slopes were positively correlated, while declining hemoglobin and greater hemoglobin variability were associated with steeper FGF23 and phosphate slopes. Phosphate slopes were associated with UACR slopes and bicarbonate slopes. Declining 25(OH)D slopes were linked with rising PTH slopes.

Conclusions:

This analysis revealed consistent relationships between CKD-MBD biomarker trajectories. Longitudinal changes in kidney function, hemoglobin, bicarbonate, UACR, and vitamin D were also associated with biomarker trajectories. Our findings confirm the multi-system nature of CKD-MBD, and provide a framework for examining potentially modifiable pathways in its progression.

Publication and source details

Original title: Modeling Longitudinal Relationships Between CKD-MBD Biomarker Trajectories with Interpretable Machine Learning in a Large Prospective CKD Cohort

Tolgay Taskapan; Hulya Taskapan; Antonio Bellasi; Sara Mahdavi; Haley Ma; Paul Tam; Tabo Sikaneta

Journal of Clinical Medicine · 2026

* Correspondence: hulyataskapan@yahoo.com (H.T.); tabosikaneta@yahoo.ca (T.S.)© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Janssen Inc.The CAN AIM to PREVENT was sponsored by Janssen Inc. which had no role in the design, conduct, or analysis of that or the current study.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:13:02.529907+00:00

DOI: 10.3390/jcm15103690 · PMC13207337